 NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBios impressive pipeline. As the COVID-19 pandemic accelerates and new variants emerge, health agencies are going to need more options to vaccinate and treat the worlds population. 